Newsroom
Off the wire.
A cutting-edge desk on the people, policy, and money moving cannabis — plus the science that cuts through the noise.
The rescheduling fight isn’t over — the hearing that decides adult-use starts Monday
Medical and FDA-approved products already moved to Schedule III. The June 29 DEA hearing decides whether the rest of the market follows.
The Crushed Desk · 4d ago · 6 min read
Wall Street is finally taking the call: Glass House cleared for the NYSE
Weeks after Trulieve became the first U.S. plant-touching operator to list on the Big Board, Glass House Brands got the nod too.
3d ago · 5 min read
Massachusetts could become the first state to repeal legalization — and it’s now on the ballot
Anti-legalization advocates turned in enough signatures to put a recreational-cannabis repeal in front of voters this November.
3d ago · 5 min read
Strikes and smoke lounges: what cannabis culture looks like in a down market
Ascend workers walked out and New Jersey cleared a consumption lounge — two snapshots of an industry growing up under pressure.
4d ago · 4 min read
The other side of the rally: receiverships, restructurings, and a fire-sale market
While the biggest names ring the NYSE bell, the middle of the market is getting restructured out from under itself.
5d ago · 5 min read
On the shelf this month: a wrestler’s multi-state rollout and a race to the bottom on price
From RVD420’s seven-state debut to Canopy chasing high potency on a budget, June’s launches show two very different bets.
6d ago · 3 min read
Nearly 200 studies in: what cannabis research actually showed in the first half of 2026
Past the press releases, the year’s peer-reviewed work points at real medical signal — and a real potency warning.
1w ago · 7 min read